Skip to main content

Advertisement

SpringerLink
Log in

Oral moxifloxacin for outpatient treatment of low-risk, febrile neutropenic patients

  • Original Article
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Objectives

Low-risk febrile neutropenic patients can be treated without hospitalization with oral antibiotic regimens. Combination regimens are recommended. Our objective was to evaluate the feasibility of quinolone monotherapy (moxifloxacin) in this setting.

Methods

In this open-label pilot study, eligible low-risk febrile neutropenic patients identified using pre-defined criteria (MASCC Risk Index) received oral moxifloxacin (400 mg) in our emergency center and were discharged after a 4–8 h observation period to ensure clinical stability. They subsequently received moxifloxacin 400 mg daily as outpatients. Success of monotherapy, outpatient management, the development of adverse events, and major medical complications were recorded.

Results

The trial was closed without reaching the target sample size of 40 patients due to slow accrual. Twenty-one evaluable patients were enrolled, with sarcoma and breast cancer being the predominant underlying neoplasms. Most patients (76%) were severely neutropenic (≤100 cells/mm3) on enrollment. There were 13 episodes (62%) of unexplained fever and eight documented infections including five episodes (24%) of bacteremia. The overall success rate of monotherapy was 95%. One patient with unexplained fever and persistent neutropenia required hospitalization and responded to alternative therapy. No significant toxicity or severe medical complications occurred.

Conclusions

Oral outpatient quinolone monotherapy for low-risk febrile neutropenic patients appears feasible and needs to be formally evaluated in large randomized clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bodey GP (1986) Infection in cancer patients: a continuing association. Am J Med 81(Suppl lA):11–26. doi:10.1016/0002-9343(86)90510-3

    Article  CAS  PubMed  Google Scholar 

  2. Chamilos G, Bamias A, Efstathiou E, Zorzou PM, Kastritis E, Kostis E et al (2005) Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin. Cancer 103:2629–2635. doi:10.1002/cncr.21089

    Article  CAS  PubMed  Google Scholar 

  3. Cometta A, Marchetti O, Calandra T, Bille J, Kern KV, Zinner S (2006) In vitro antimicrobial activity of moxifloxacin against bacterial strains isolated from blood and neutropenic cancer patients. Eur J Clin Microbiol Infect Dis 25:537–540. doi:10.1007/s10096-006-0175-2

    Article  CAS  PubMed  Google Scholar 

  4. Elting LS, Lu C, Escalante CP, Giordana SH, Trent JC, Cooksley C et al (2008) Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia. J Clin Oncol 26:606–611. doi:10.1200/JCO.2007.13.8222

    Article  PubMed  Google Scholar 

  5. Escalante CP, Weiser MA, Manzullo E, Benjamin R, Rivera E, Lam T et al (2004) Outcomes of treatment pathways in outpatient treatment of low-risk febrile neutropenic cancer patients. Support Care Cancer 12:657–662

    PubMed  Google Scholar 

  6. Hughes WT, Armstrong D, Bodey GP, Bow EF, Brown AE, Calandra T et al (2002) 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34:730–751. doi:10.1086/339215

    Article  PubMed  Google Scholar 

  7. Innes HE, Smith DB, O’Reilly SM, Clark PI, Kelly V, Marshall E (2003) Oral antibiotics with early hospital discharge compared with inpatient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomized controlled single centre study. Br J Cancer 89:43–49. doi:10.1038/sj.bjc.6600993

    Article  CAS  PubMed  Google Scholar 

  8. Johnson TN, DeJesus YA, McMahon L, Rolston KV, Row MB (2008) Outpatient management of febrile neutropenia: is it safe yet? J Support Oncol 6:219–220

    PubMed  Google Scholar 

  9. Kamana M, Escalante C, Mullen CA, Frisbee-Hume S, Rolston KV (2005) Bacterial infections in low-risk, febrile neutropenic patients. Cancer 104:422–426. doi:10.1002/cncr.21144

    Article  PubMed  Google Scholar 

  10. Kern KV (2006) Risk assessment and treatment of low-risk patients with febrile neutropenia. Clin Infect Dis 15:533–540. doi:10.1086/499352

    Article  Google Scholar 

  11. Klastersky J, Paesmans M, Georgala A, Muanza F, Plehiers DL et al (2006) Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. J Clin Oncol 25:4129–4134. doi:10.1200/JCO.2005.03.9909

    Article  Google Scholar 

  12. Klastersky J, Paesmans M, Rubenstein E, Boyer M, Elting L, Feld R et al (2000) The MASCC Risk Index: a multinational scoring system to predict low-risk febrile neutropenic cancer patients. J Clin Oncol 18:3038–3051

    CAS  PubMed  Google Scholar 

  13. Malik IA, Khan WA, Karim M, Azziz A, Khan MA (1995) Feasibility of outpatient management of fever in cancer-patients with low-risk neutropenia: results of a prospective randomized trial. Am J Med 98:224–231. doi:10.1016/S0002-9343(99)80367-2

    Article  CAS  PubMed  Google Scholar 

  14. Mullen CA, Petropoulos D, Roberts WM, Rytting M, Ziph T, Chan KW (1999) Outpatient treatment of febrile neutropenia in low risk pediatric cancer patients. Cancer 86:126–134. doi:10.1002/(SICI)1097-0142(19990701)86:1<126::AID-CNCR18>3.0.CO;2-1

    Article  CAS  PubMed  Google Scholar 

  15. National Committee for Clinical Laboratory Standards (2002) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A5. (NCCLS) Wayne, PA

  16. Petrilli SA, Carlesse FA, Pereira CAP (2007) Oral gatifloxacin in the outpatient treatment of children with cancer fever and neutropenia. Pediatr Blood Cancer 49:682–686. doi:10.1002/pbc.21124

    Article  PubMed  Google Scholar 

  17. Quezada G, Sunderland T, Chan KW, Rolston K, Mullen CA (2007) Medical and non-medical barriers to outpatient treatment of fever and neutropenia in children with cancer. Pediatr Blood Cancer 48:273–277. doi:10.1002/pbc.20774

    Article  PubMed  Google Scholar 

  18. Rolston K (1999) New trends in patient management: risk-based therapy for febrile patients with neutropenia. Clin Infect Dis 29:515–521. doi:10.1086/520247

    Article  CAS  PubMed  Google Scholar 

  19. Rolston KVI, Frisbee-Hume S, LeBlanc BM, Streeter H, Ho DH (2002) Antimicrobial activity of novel des-fluoro (6) quinolone, garenoxacin (BMS-284756), compared to other quinolones, against clinical isolates from cancer patients. Diagn Microbiol Infect Dis 44:187–194. doi:10.1016/S0732-8893(02)00433-9

    Article  CAS  PubMed  Google Scholar 

  20. Rolston KVI, Frisbee-Hume S, LeBlanc B, Streeter H, Ho DH (2003) In vitro antimicrobial activity of moxifloxacin compared to other quinolones against recent clinical bacterial isolates from hospitalized and community-based cancer patients. Diagn Microbiol Infect Dis 47:441–449. doi:10.1016/S0732-8893(03)00115-9

    Article  CAS  PubMed  Google Scholar 

  21. Rolston KVI, Manzullo EF, Elting LS, Frisbee-Hume SE, McMahon L, Theriault RL et al (2006) Once daily, oral, outpatient quinolone monotherapy for low-risk cancer patients with fever and neutropenia. Cancer 106:2489–2494. doi:10.1002/cncr.21908

    Article  CAS  PubMed  Google Scholar 

  22. Rubenstein EB, Rolston K, Benjamin RS, Loewy J, Escalante E, Manzullo E et al (1993) Outpatient treatment of febrile episodes in low risk neutropenic cancer patients. Cancer 71:3640–3646. doi:10.1002/1097-0142(19930601)71:11<3640::AID-CNCR2820711128>3.0.CO;2-H

    Article  CAS  PubMed  Google Scholar 

  23. Sebban C, Dussart S, Fuhrmann C, Ghesquieres H, Rodrigues I, Geoffrois L (2008) Oral moxifloxacin or intravenous ceftriaxone for the treatment of low-risk neutropenic fever in cancer patients suitable for early hospital discharge. Support Care Cancer 16:1017–1023. doi:10.1007/s00520-007-0383-z

    Article  PubMed  Google Scholar 

  24. Segal BH, Freifeld AG, Baden LR, Brown AE, Casper C, Dubberke E et al (2008) Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw 6:122–174

    PubMed  Google Scholar 

  25. Talcott JA, Siegel RD, Finberg R, Goldman L (1992) Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 10:316–322

    CAS  PubMed  Google Scholar 

  26. Vidal L, Paul M, Ben dor I, Soares-Weiser K, Leibovici L (2004) Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients: a systematic review and meta-analysis of randomized trials. J Antimicrob Chemother 54:29–37. doi:10.1093/jac/dkh303

    Article  CAS  PubMed  Google Scholar 

  27. von Baum H, Sigge A, Bommer M, Kern WV, Marre R, Döhner H (2006) Moxifloxacin prophylaxis in neutropenic patients. J Antimicrob Chemother 58:891–894. doi:10.1093/jac/dkl320

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd. (Unit 1460), Houston, TX, 77030, USA

    Kenneth V. I. Rolston

  2. Department of Research Education and Regulatory Management, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 77030, USA

    Susan E. Frisbee-Hume

  3. Department of Sarcoma Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 77030, USA

    Shreyaskumar Patel & Robert S. Benjamin

  4. Department of General Internal Medicine, Ambulatory Treatment and Emergency Center, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 77030, USA

    Ellen F. Manzullo

Authors
  1. Kenneth V. I. Rolston
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Susan E. Frisbee-Hume
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shreyaskumar Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ellen F. Manzullo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Robert S. Benjamin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kenneth V. I. Rolston.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rolston, K.V.I., Frisbee-Hume, S.E., Patel, S. et al. Oral moxifloxacin for outpatient treatment of low-risk, febrile neutropenic patients. Support Care Cancer 18, 89–94 (2010). https://doi.org/10.1007/s00520-009-0634-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-009-0634-2

Keywords

Search

Navigation